Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dasani enhanced water

This article was originally published in The Tan Sheet

Executive Summary

Coca-Cola announces May 31 the launch of Dasani Plus vitamin-enhanced flavor water beverages. The zero-calorie beverage comes in three flavors: Refresh + Revive, a kiwi strawberry flavor with 10% the recommended daily intake of vitamins B3, B6 and B12; Cleanse + Restore, pomegranate blackberry flavor containing 10% of the RDI per serving of vitamins E, B3, B6, B12 and 1 g of fiber; and Defend + Protect, orange tangerine flavor providing 10% of the RDI for vitamin E and zinc. Dasani Plus, in a 20 fl. oz bottle, will carry an SRP "competitive within the enhanced water category," the Atlanta-based firm says. Coca-Cola announced plans May 25 to acquire vitaminwater manufacturer Energy Brands (1"The Tan Sheet" May 28, 2007, In Brief)...

You may also be interested in...

Coca-Cola expands reach

Coca-Cola announces May 25 it will acquire Energy Brands Inc., known as glaceau, for $4.1 bil. in cash. Glaceau's, which owns brands such as vitaminwater,smartwater and vitaminenergy, will operate as a separate business unit within Coca-Cola North America. "This structure will allow glaceau to continue to win in the marketplace by maximizing its focus, speed, sales and execution capabilities," Coca-Cola says in a release. The transaction is expected to close in the summer, subject to customary regulatory review. Glaceau most recently introduced vitaminwater xxx to the marketplace. The product contains antioxidants acai, blueberry and pomegranate (1"The Tan Sheet" April 2, 2007, p. 14)...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts